Lack of Telomerase Reverse Transcriptase Promoter C228T and C250T Hotspot Mutations in Colorectal Cancer Patients in Türkiye
Received Date : 07 Jun 2021
Accepted Date : 05 May 2022
Available Online : 01 Jun 2022
Doi: 10.37047/jos.2021-84899 - Article's Language: EN
J Oncol Sci. 2022;8(2):57-62
This is an open access article under the CC BY-NC-ND license
Objective: Telomerase reverse transcriptase (TERT) is one of the catalytic subunits of the telomerase enzyme involved in the lengthening of telomeres during cell division. Two hotspot mutations in the promoter region of the TERT gene, C228T and C250T have been observed in many different types of cancer. Besides, a limited number of available studies are related to colorectal cancer. However, no study to date has analyzed these mutations in the Turkish population. Hence, this study aimed to determine the frequency of C228T and C250T hotspot mutations in Turkish patients with colorectal cancer. Material and Methods: Tumors and adjacent healthy tissues of 43 colorectal cancer patients were analyzed in the study material. After genomic DNA extraction, 163 bp DNA fragment of the TERT promoter region was amplified by polymerase chain reaction (PCR) method. PCR products were sequenced using the bi-directional Sanger technique and a wildtype TERT promoter sequence obtained from the National Center for Biotechnology Information database was used for the comparison and detection of mutations. Results: Sequence analysis revealed no mutations in the promoter region of the TERT gene in colorectal cancer tissues or in healthy tissues. Conclusion: These findings of the study suggest that colorectal cancer in the Turkish population is not associated with the TERT promoter C228T and C250T hotspot mutations.
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [Crossref]  [PubMed] 
  2. Inamura K. Colorectal cancers: an update on their molecular pathology. Cancers (Basel). 2018;10(1):26. [Crossref]  [PubMed]  [PMC] 
  3. Gurer T, Aytekin A, Alahdab Y. Arf6 expression in the tissues of patients with colorectal cancer. International Journal of Human Genetics. 2020;20(3):132-137. [Link] 
  4. Min J, Shay JW. TERT promoter mutations enhance telomerase activation by long-range chromatin interactions. Cancer Discov. 2016;6(11):1212-1214. [Crossref]  [PubMed]  [PMC] 
  5. Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res Rev Mutat Res. Jan-Mar 2017;771:15-31. [Crossref]  [PubMed] 
  6. Colebatch AJ, Dobrovic A, Cooper WA. TERT gene: its function and dysregulation in cancer. J Clin Pathol. 2019;72(4):281-284. [Crossref]  [PubMed] 
  7. Jung SJ, Park JH, Hwang I, Lee JH. Different TERT expression between colorectal adenoma and serrated polyp. Medicina (Kaunas). 2020;56(9):463. [Crossref]  [PubMed]  [PMC] 
  8. Trybek T, Kowalik A, Góźdź S, Kowalska A. Telomeres and telomerase in oncogenesis. Oncol Lett. 2020;20(2):1015-1027. [Crossref]  [PubMed]  [PMC] 
  9. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11(5):319-330. [Crossref]  [PubMed] 
  10. Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019;38(34):6172-6183. [Crossref]  [PubMed]  [PMC] 
  11. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012;498(2):135-146. [Crossref]  [PubMed]  [PMC] 
  12. Garcia-Aranda C, de Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer. 2006;106(3):541-551. [Crossref]  [PubMed] 
  13. Millar SE. Cell biology: The not-so-odd couple. Nature. 2009;460(7251):44-45. [Crossref]  [PubMed] 
  14. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8(1):137-142. [Crossref]  [PubMed] 
  15. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-961. [Crossref]  [PubMed] 
  16. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-959. [Crossref]  [PubMed]  [PMC] 
  17. Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013;73(24):7162-7167. [Crossref]  [PubMed]  [PMC] 
  18. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021-6026. [PubMed]  [PMC] 
  19. Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562-6. [Crossref]  [PubMed]  [PMC] 
  20. Quaas A, Oldopp T, Tharun L, et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch. 2014;465(6):673-677. [Crossref]  [PubMed] 
  21. Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8(1):69. [Crossref]  [PubMed]  [PMC] 
  22. Panebianco F, Nikitski AV, Nikiforova MN, Nikiforov YE. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Med. 2019;8(13):5831-5839. [Crossref]  [PubMed]  [PMC] 
  23. Rusinek D, Pfeifer A, Cieslicka M, et al. TERT promoter mutations and their impact on gene expression profile in papillary thyroid carcinoma. Cancers (Basel). 2020;12(6):1597. [Crossref]  [PubMed]  [PMC] 
  24. Qu Y, Shi L, Wang D, et al. Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int J Cancer. 2014;134(12):2993-2994. [Crossref]  [PubMed] 
  25. Zhao Y, Gao Y, Chen Z, Hu X, Zhou F, He J. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int J Cancer. 2014;134(2):493-494. [Crossref]  [PubMed] 
  26. Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. Jul 2014;7:47. [Crossref]  [PubMed]  [PMC] 
  27. Bell RJ, Rube HT, Xavier-Magalhães A, et al. Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res. 2016;14(4):315-323. [Crossref]  [PubMed]  [PMC] 
  28. Shida W, Tateishi H, Tahara Y, et al. Antileukemic activity of twig components of caucasian beech in Turkey. Molecules. 2019;24(21):3850. [Crossref]  [PubMed]  [PMC] 
  29. Gezici S, Sekeroglu N. Regulation of microRNAs by natural products and bioactive compounds obtained from common medicinal plants: novel strategy in cancer therapy. Indian Journal of Pharmaceutical Education and Research. 2017;51(3):483-488. [Crossref] 
  30. Arantes LMRB, Cruvinel-Carloni A, de Carvalho AC, et al. TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients. Front Oncol. 2020;10:1275. [Crossref]  [PubMed]  [PMC] 
  31. Gramatzki D, Felsberg J, Hentschel B, et al. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? Eur J Cancer. Apr 2021;147:84-94. [Crossref]  [PubMed] 
  32. Cruvinel-Carloni A, Yamane L, Scapulatempo-Neto C, Guimarães D, Reis RM. Absence of TERT promoter mutations in colorectal precursor lesions and cancer. Genet Mol Biol. 2018;41(1):82-84. [Crossref]  [PubMed]  [PMC] 
  33. Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. July 2013;4:2185. [Crossref]  [PubMed] 
  34. Liu T, Liang X, Björkholm M, Jia J, Xu D. The absence of TERT promoter mutations in primary gastric cancer. Gene. 2014;540(2):266-267. [Crossref]  [PubMed] 
  35. Siraj AK, Bu R, Iqbal K, et al. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population. Genomics. 2020;112(2):1746-1753. [Crossref]  [PubMed] 
  36. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 2015;21(1):311-317. [Crossref]  [PubMed]  [PMC]